Biotech Revolution: Scientific Progress Now Counts as Financial Asset
April 20, 2026 — Biotech valuation transforms as scientific progress becomes measurable financial asset under GAAP accounting. Oncotelic Therapeutics leads shift with $1B+ pipeline value.